


Risk Factors for PsA

Effect Size^a



Note: Risk factors for the development of PsA in patients with PsO are from cohort studies unless otherwise stated.

Other risk factors may include family history of PsA, smoking, and duration of PsO¹

The Effects of Obesity in PsA

Compared with patients with PsA who are of a healthy weight, those with comorbid obesity have higher³:

- Joint counts
- HAQ-DI
- CRP
- cDAPSA
- PsA may lead to weight gain as patients may be less likely to be physically active⁴
- Excess body weight may place additional mechanical stress on the joints and heighten the likelihood of microtrauma^{4,5}




Irreversible Joint Damage in PsA⁶

Can happen with a delay in diagnosis of just

6 months

Can lead to worse long-term physical function



Treatment of PsA leads to improvements in QoL for patients⁷

Simple Mnemonic to Aid in Screening of PsA⁸

Joint

PAIN • **STIFFNESS** • **AXIAL**

after waking in the morning, or after a period of inactivity. Swelling/Sausage digit (dactylitis) involvement

Examples of PsA Screening Tools Include⁹:



PASE

Psoriatic Arthritis Screening and Evaluation



PEST

Psoriasis Epidemiology Screening Tool



EARP

The Early Psoriatic Arthritis Screening Questionnaire

AAD/NPF Recommendations for Dermatologists¹⁰



Patients with PsO should be **informed about the association between PsO and PsA**



PsA should be **considered in all patients with cutaneous PsO**



Patients with signs and symptoms suspicious for PsA should be **fully evaluated for PsA**.

Initiate appropriate PsA therapy if comfortable with the diagnosis or otherwise consult with a rheumatologist for assessment and management



Explore the other infographics in the **Comorbidities in Psoriasis** series



^aAdjusted for other covariates; ^bBMI ≥ 35.0 kg/m² vs. normal (BMI < 25.0 kg/m²); ^cTime varying exposure; ^dIntergluteal/perianal involvement; ^ePASI score > 20 vs. < 10 ; ^fValues based on the general population.

AAD=American Academy of Dermatology; BMI=Body Mass Index; cDAPSA=Clinical Disease Activity Index for Psoriatic Arthritis; CI=Confidence Interval; CRP=C-Reactive Protein; HAQ-DI=Health Assessment Questionnaire Disability Index; HR=Hazard Ratio; NPF=National Psoriasis Foundation; PASI=Psoriasis Area and Severity Index; PsA=Psoriatic Arthritis; PsO=Psoriasis; QoL=Quality of Life; RR=Relative Risk.

Female icon has been generated with the use of AI

1. Scher JU, et al. *Nat Rev Rheumatol*. 2019;15(3):153-166. 2. Wilson FC, et al. *Arthritis Rheum*. 2009;61(2):233-239. 3. Kumthekar A, Ogdie A. *Rheumatol Ther*. 2020;7(3):447-456. 4. McVinnie DS. *Br J Pain*. 2013;7(4):163-170. 5. Williams JC, et al. *Ther Adv Musculoskelet Dis*. 2024;16:1759720X241271886. 6. Haroon M, et al. *Ann Rheum Dis*. 2015;74(6):1045-1050. 7. Mease PJ, Menter MA. *J Am Acad Dermatol*. 2006;54(4):685-704. 8. Cohen JM, et al. *J Am Acad Dermatol*. 2025;72(5):905-906. 9. Iragorri N, et al. *Rheumatology (Oxford)*. 2019;58(4):692-707. 10. Elmetts CA, et al. *J Am Acad Dermatol*. 2019;80(4):1073-1113.